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SAINT LOUIS UNIVERSITY SCHOOL OF LAW

BEYOND BIDIL: THE EXPANDING EMBRACE OF RACE IN BIOMEDICAL
RESEARCH AND PRODUCT DEVELOPMENT
JONATHAN KAHN*
I. INTRODUCTION
In 2005, the U.S. Food and Drug Administration (FDA) approved the
drug, BiDil®, for treatment of heart failure in “black” patients.1 The
approval of this first, and currently only, race-specific drug provoked an
energetic and sustained discussion of the propriety of using racial categories
in drug development in a wide array of media and professional journals.2
BiDil is the prototype of using race as a placeholder during the “meantime”
of pharmacogenomic development. As one article in the journal Science
stated at the time, “By backing BiDil, the FDA panel gave another push to
pharmacogenomics, an approach that promises to revolutionize both drug
discovery and patient care.”3
The 2005 FDA approval was based on results from the AfricanAmerican Heart Failure Trial (A-HeFT)4 that were published the previous
November in the New England Journal of Medicine.5 The trial design itself
was groundbreaking because it included only self-identified African

* J.D., Ph.D., Professor of Law, Hamline University School of Law. I would like to thank the
participants at the Saint Louis University Health Law Symposium: “Living in the Genetic Age,”
and the participants at the Annual Meeting of the Science and Democracy Network for their
helpful comments and suggestions. Work on this article was supported in part by the Ethical,
Legal, and Social Implications Research Program, National Human Genome Research
Institute (Grant number R03-HG004034-02).
1. News Release, U.S. Food & Drug Admin., FDA Approves BiDil Heart Failure Drug for
Black Patients (June 23, 2005) [hereinafter FDA News Release], http://www.fda.gov/News
Events/Newsroom/PressAnnouncements/2005/ucm108445.htm.
2. See, e.g., Jonathan Kahn, How a Drug Becomes “Ethnic”: Law, Commerce, and the
Production of Racial Categories in Medicine, YALE J. HEALTH POL’Y L. & ETHICS, Winter 2004, at
3, 33 (discussing the use of race in the development of BiDil). See also Timothy Caulfield &
Simrat Harry, Popular Representations of Race: The News Coverage of BiDil, 36 J.L. MED. &
ETHICS 485, 485-86 (2008) (reporting that when the term “BiDil” was searched in the LexisNexis database it yielded a total of 167 U.S. newspaper articles).
3. Robert F. Service, Going from Genome to Pill, 308 SCIENCE 1858, 1858 (2005).
4. FDA News Release, supra note 1.
5. See Anne L. Taylor et al., Combination of Isosorbide Dinitrate and Hydralazine in
Blacks with Heart Failure, 351 NEW ENG. J. MED. 2049, 2050 (2004).
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Americans.6 The results therefore give the impression that BiDil works only
in African Americans. This is clearly not the case. The trial investigators
themselves concede that BiDil will work in people regardless of race.7
Without a comparison population, the investigators cannot even claim that
the drug works differently in African Americans than in any other group.8
Nonetheless, NitroMed, the corporate sponsor of BiDil, applied for and
received FDA approval for the drug with a race-specific indication to treat
heart failure only in African Americans. Pervasive media coverage of the
announcement of the results and the FDA approval also focused on the
racial-specificity of the drug, often explicitly claiming that it shows race is
genetic.9
Underlying the trial design, however, is a race-specific patent issued by
the United States Patent and Trademark Office (PTO) on October 15,
2002, that is premised on a biological or genetic conception of race.10 It
confers intellectual property protection for the method of using the drug to
treat heart failure in African Americans until 2020.11 A previous patent
issued in 1987 to the same inventor for the same method of using the same
drug in the general population without regard to race expired in 2007.12
Therefore, in this case, bringing race into the patent system allowed the
inventor to gain a substantial extension of his intellectual property
monopoly.
Both the patent and the drug trial for BiDil relate their race-specific
design to a search for genetic markers underlying heart disease. On the
6. Id.
7. See Denise Gellene, Heart Pill Intended Only for Blacks Sparks Debate, L.A. TIMES,
June 16, 2005 at C1 (reporting that trial investigator and cardiologist Jay N. Cohn prescribes
the generic drugs that make up BiDil to white patients as well, saying “I actually think
everybody should be using it.”).
8. Id.
9. See Jonathan Kahn, Misreading Race and Genomics after BiDil, 37 NATURE GENETICS
655, 655 (2005) [hereinafter Kahn, Misreading Race].
10. Methods of Treating & Preventing Congestive Heart Failure with Hydralazine
Compounds & Isosorbide Dinitrate or Isosorbide Mononitrate, U.S. Patent No. 6,465,463
(filed Sept. 8, 2000) (issued Oct.15, 2002).
11. Id.; U.S. Patent & Trademark Office, General Information Concerning Patents (Jan.
2005), http://www.uspto.gov/web/offices/pac/doc/general/index.html (explaining that the
term of a new patent in the United States is 20 years from the date on which the patent
application was filed). See also Kahn, Misreading Race, supra note 9, at 655 (noting that
NitroMed, Inc. also “holds a patent for a non-race-specific use of BiDil” that expires in 2007).
12. Method of Reducing Mortality Associated with Congestive Heart Failure Using
Hydralazine & Isosorbide Dinitrate, U.S. Patent No. 4,868,179 (filed Apr. 22, 1987) (issued
Sept. 19, 1989). See also Jonathan Kahn, From Disparity to Difference: How Race-Specific
Medicines May Undermine Policies to Address Inequalities in Health Care, 15 S. CAL.
INTERDISC. L.J. 105, 112 (2005) (noting that through receiving a new, race-based patent,
NitroMed extended their monopoly on BiDil).
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one hand, this reflects an approach, largely sanctioned by many in the
emerging field of pharmacogenomics,13 of using race instrumentally as a
surrogate to get at underlying genetic variation that could be ultimately
identified without reference to race. On the other hand, for the foreseeable
future, it presents the immediate reality of race being used as a quasigenetic category to obtain patents and drug approvals and to increase
market share.
The question then becomes, is BiDil an anomaly or a harbinger of things
to come? The answer, it turns out, is a little of both. This article will
consider two prominent and recent examples of the continued use of race in
biomedical research and product development. The first is the beta-blocker
Bystolic® (nebivolol), a drug used to treat cardiovascular conditions such as
hypertension.14 It treats similar conditions as BiDil, but is a different class of
drug.15 Unlike BiDil, Bystolic is not a combination of two generic drugs but
rather has its own independent patent on the actual composition of matter
that comprises the drug itself.16 The marketers of Bystolic, however, have
taken a page from the BiDil playbook, as it were, in using race to
differentiate their product in a crowded marketplace by mentioning the
drug’s effect with respect to race in its package insert.17 At this point, there
are no race-specific patents issued for Bystolic, but several are pending
before the PTO.18
The second example of the use of race in biomedical research and
product development involves the drug warfarin, a widely prescribed bloodthinning agent. Warfarin itself is a generic drug and not directly the subject

13. Wolfgang Sadee, Drug Therapy and Personalized Health Care: Pharmacogenomics
in Perspective, 25 PHARMACEUTICAL RES. 2713, 2714 (2008) (noting that pharmacogenomics
incorporates pharmacogenetics—the “study of genetic causes of variability in drug
response”—in order to fulfill pharmacogenomics’ broader goal of using genetics to aid “drug
discovery, development, and therapy”). See also Francis S. Collins, What We Do and Don’t
Know About ‘Race’, ‘Ethnicity’, Genetics and Health at the Dawn of the Genome Era, 36 NAT.
GENETICS S13 (2004).
14. FOREST PHARMACEUTICALS, INC., BYSTOLIC® (2008) (package insert), available at
http://www.frx.com/pi/Bystolic_pi.pdf.
15. See NITROMED, INC., BIDIL® PACKAGE INSERT (2005), available at http://www.access
data.fda.gov/drugsatfda_docs/label/2005/020727lbl.pdf.
16. Compositions Containing Micronized Nebivolol, U.S. Patent No. 5,759,580 (filed
Feb. 10, 1995) (issued June 2, 1998).
17. See FOREST PHARMACEUTICALS, INC., supra note 14 at 6 (noting that “[e]ffectiveness
was established in Blacks”).
18. See, e.g., Hyroxylated Nebivolol Metabolites, U.S. Patent Application No.
20070014733 (filed Jan. 18, 2007) (claiming “[a] method of reducing mortality associated
with cardiovascular disease in a black patient comprising administering to the black patient a
therapeutically effective amount of . . . nebivolol”). See also Glucuronidated Nebivolol
Metabolites, U.S. Patent Application No. 20070014734 (filed Jan. 18, 2007).
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of race-specific marketing.
In recent years, however, biomedical
researchers have discovered several specific genetic variations that have a
significant impact on patient response to warfarin.19 Race becomes a factor
for warfarin through the field of pharmacodiagnostics—the development of
tests which identify whether individuals have certain genetic variants that
may affect drug response.20 In the past several years many companies have
come forward offering such tests.21 Some studies have shown that these
genetic variations appear at different frequencies in different racial groups.22
One company, AutoGenomics, has explicitly embraced such racial variation
as a basis for distinguishing its product from other genetic tests on the
market.23 In addition, PharmiGene, a company in Taiwan, reportedly has a
race-specific patent pending concerning its particular method of testing for
genetic variations in warfarin response.24 Again, like BiDil, race is being
used to create market opportunity and gain patent protection; but unlike
BiDil, we do not specifically see race being used to extend or resurrect
patent protection for existing products.
II. BYSTOLIC: MAKING THE EIGHTEENTH BETA-BLOCKER STAND OUT
Ethnic niche marketing is well-established in American product
development and advertising. Commercial biotechnology seems to have
discovered the potential of such marketing in the case of BiDil. It is here
that the model of BiDil, for all its distinctiveness, has most clearly taken hold.
Big Pharma is plagued with a plethora of “me-too” products. Once one
company develops a particular blockbuster drug, whether in pain relief (e.g.
Cox-2 inhibitors) or cardiovascular health (e.g. statins), others clamber to
join the bandwagon by producing biologically similar, yet legally distinct
(i.e. non-patent-infringing) pharmaceutical products. With numerous similar
products on the market, it becomes essential for each producer to try to

19. See Warfarin, Race, and the Business of Pharmacodiagnostics, infra Part III. See also
Ann K. Daly, Pharmacogenomics of Anticoagulants: Steps toward Personal Dosage, 1
GENOME MED. 10.1, 10.1 (2009).
20. See H. Ngow et al., Role of Pharmacodiagnostic of CYP2C9 Variants in the
Optimization of Warfarin Therapy in Malaysia: A 6-Month Follow-Up Study, 38 XENOBIOTICA
641, 642-43 (2008).
21. See Turna Ray, Competition Heats Up in Warfarin Dx Market as New Tests Seek FDA
OK, PHARMACOGENOMICS REP., Oct. 10, 2007, http://www.genomeweb.com/dxpgx/
competition-heats-warfarin-dx-market-new-tests-seek-fda-ok.
22. See infra notes 71-75 and accompanying text.
23. See Ray, supra note 21.
24. Press Release, Pharmigene Obtains European Patent for Genetic Discovery Predicting
Warfarin Sensitivity (Mar. 24, 2009), http://pharmalicensing.com/public/press/view/1237856
381_49c8307dbb1e6/pharmigene-obtains-european-patent-for-genetic-discovery-predictingwarfarin-sensitivity.
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distinguish its drug from the competition. Traditionally, this was done
through claims of improved efficacy or lesser side effects. More recently,
pharmaceutical and medical device companies have discovered race as a
means to distinguish their products (and patents) as well. In the realm of
pharmaceuticals, particularly striking is the beta-blocker, nebivolol,
marketed as Bystolic by Forest Laboratories.
Beta-blockers comprise a class of drugs that have been used for
decades to treat hypertension and other cardiovascular conditions such as
heart failure.25 There are currently at least eighteen beta-blockers on the
market, several available as low-cost generics.26 In such a market, it seems
striking, therefore, that Forest Laboratories would take the time and incur the
expense to bring yet another beta-blocker to the FDA for approval in 2007.
Yet this is exactly what it did with nebivolol, a beta-blocker that had been
used in Europe for over a decade but whose original inventor, Janssen
Pharmaceutical NV, had never sought to bring it to the American market.27
Forest received approval for nebivolol in December, 2007 and began
marketing it as Bystolic shortly thereafter.28 In numerous press releases and
discussions of funded clinical research, Forest and its surrogates (including
the doctors conducting Forest-sponsored clinical trials) emphasized two key
aspects of Bystolic’s profile in order to differentiate it from the other
seventeen beta-blockers on the market: First, it has fewer side effects—in
particular, fewer incidences of erectile dysfunction;29 and second, it worked
well in African Americans in a drug trial.30 This latter claim is particularly
significant because there has been ongoing debate in the medical literature
about the relative efficacy of beta-blockers in self-identified African-

25. See generally Michael B. Fowler, Hypertension, Heart Failure, and Beta-Andrenergic
Blocking Drugs, 52 J. AM. C. CARDIOLOGY 1073, 1073 (2008) (commenting on the use of
beta-blockers for hypertension and heart failure).
26. Brian Orelli, New Beta Blocker on the Crowded Street, MOTLEY FOOL, Dec. 17,
2007, http://www.fool.com/investing/dividends-income/2007/12/19/new-beta-blocker-in-acrowded-forest.aspx.
27. See Press Release, Forest Laboratories, Inc., Bystolic™, a Novel Beta Blocker, Is Now
Approved by the FDA for the Treatment of Hypertension (Dec. 18, 2007), http://www.frx.com/
news/PressRelease.aspx?ID=1088188.
28. See id.
29. Press Release, Forest Laboratories, Inc., Nebivolol Lowers Blood Pressure in Mild-toModerate Hypertensive Patients as Demonstrated in a Study Published in the Journal of
Clinical Hypertension (Sept. 4, 2007), http://www.frx.com/news/PressRelease.aspx?ID=104
7743.
30. Press Release, Forest Laboratories, Inc., UPDATE: Nebivolol Lowers Blood Pressure in
African Americans With Stage I-II Hypertension as Demonstrated in a Study Published in the
Journal of Clinical Hypertension (Nov. 1, 2007), http://www.frx.com/news/PressRelease.aspx?
ID=1071168.

SAINT LOUIS UNIVERSITY SCHOOL OF LAW

66

SAINT LOUIS UNIVERSITY JOURNAL OF HEALTH LAW & POLICY

[Vol. 3:61

American patient populations.31 Being able to make affirmative claims
about the efficacy of Bystolic in African Americans thus immediately
distinguished it from the pack of other beta-blockers. Forest Laboratories
made this claim based on a race-specific drug trial, mimicking in many
respects the A-HeFT trial for BiDil that tested Bystolic exclusively in selfidentified African Americans.32
As Doctor Elijah Saunders stated in reporting the results of this racespecific study, “There is a perception that beta blockers are not effective in
blacks. But this study refutes that idea.”33 Dr. Paul Underwood, a Phoenix
cardiologist and President of the Association of Black Cardiologists (which
co-sponsored the A-HeFT trial with NitroMed) praised the nebivolol study,
stating, “We’re excited to add another therapeutic tool to the
armamentarium in the treatment of high blood pressure in AfricanAmericans.”34 An article on the study in the web-based journal MedScape
Today, quoted Saunders as stating that
The findings of this study are important considering the excessive burden of
high blood pressure in African Americans and the need for new treatment
options . . . Advances like this in the beta blocker class are particularly

important because African Americans have a historically poor response to
beta blocker therapy for hypertension.35

The article went on to note that “[d]ata suggesting that beta-blockers as a
class are less effective than other agents in black patients, as well as the
association with poor tolerability and adverse metabolic effects, have led to
underuse of traditional beta-blockers in black patients.”36 What is striking
here is the juxtaposition of the concepts of efficacy and underuse.
“Underuse” implies that more blacks should be using beta-blockers but do
not. The tension here is that if blacks “have a historically poor response to
beta blockers,” then lesser use is not “underuse,” but rather simply reflects

31. See, e.g., Sidney Goldstein, Beta Blocker Therapy in African American Patients with
Heart Failure, 9 HEART FAILURE REVIEWS 161, 161 (2004). See also Paul G. Shekelle et al.,
Efficacy of Angiotensin-Converting Enzyme Inhibitors and Beta-Blockers in the Management of
Left Ventricular Systolic Dysfunction According to Race, Gender, and Diabetic Status: A MetaAnalysis of Major Clinical Trials, 41 J. AM. C. CARDIOLOGY 1529, 1529 (2003); Clyde W.
Yancy, Race-Based Therapeutics, 10 CURRENT HYPERTENSION REP. 276, 276 (2008).
32. See Elijah Saunders et al., The Efficacy and Tolerability of Nebivolol in Hypertensive
African American Patients, 9 J. CLINICAL HYPERTENSION 866, 867 (2007).
33. Daily News Central, Beta Blocker Controls High Blood Pressure in Blacks (July 18,
2005), http://health.dailynewscentral.com/content/view/1308/63.
34. Id.
35. Linda Brookes, New Drug Algorithms, New Drug Approvals, New Drugs: New Data
Reported as Nebivolol Moves Toward Launch in the United States, MedScape.com (Jan. 17,
2008), http://www.medscape.com/viewarticle/568786_4 (emphasis added).
36. Id. (emphasis added).
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an appropriate level of use due to differential response. As framed here, the
advance seems to be as much about opening up the beta-blocker market to
greater use by blacks as to finding a distinctive new therapy—or rather, the
distinctiveness of the therapy opens up the market. In this regard, the
purportedly poor response of blacks to beta-blockers becomes a market
opportunity.
In February of 2008, Dr. Saunders gave a presentation on Bystolic to
pharmacists in Pennsylvania titled, “The Treatment of Hypertension in the
Very Tough to Treat Patient (obese, diabetic, African-American).”37 The
promotional material emphasizes that “Bystolic is a totally unique and novel
Beta-Blocker that is cardio selective and is a vasodilator.”38 Here the
promoters of Bystolic have linked novelty, difficulty, and race. The typical
“tough” patient is African American. On one hand, the presentation clearly
aims at helping a racially identified population that might need better
therapy. Dr. Saunders, himself African American, is a distinguished
professor of Medicine at the University of Maryland and has demonstrated
over his long career a commitment to helping improve the health of minority
communities.39 On the other hand, the presentation frames African
Americans as a problem, akin to such undesirable physical states as obesity
and diabetes. The presentation does not simply link Bystolic to race, it
implies it will make a “tough” racial group, African Americans, not only
more treatable but more tractable—i.e. less “tough.” All this as a means
not simply to promote Bystolic, but to differentiate it from what other betablockers on the marker can (or cannot) do.
The positive results from the African-American nebivolol trial have
provided the basis for its marketing claims and also for two race-specific
patent applications currently pending before the U.S. Patent and Trademark
Office.40 These patent applications, however, are not quite the same as the
patents related to BiDil. They are rather hybrids, containing claims
regarding the efficacy of nebivolol in a general population early on, and
then later adding race-specific claims pertaining to a particular type of
efficacy in “black patient[s].”41 Thus, they are both affirmatively used to
claim specific racialized territory of intellectual property, but also used
defensively, by adding a concentric ring of protection to the battlements of

37. PA Pharmacists Ass’n, Invitation to Program on Bystolic (Feb. 14, 2008), available at
www.papharmacists.com/2-14-08_%20a%20program%20on%20Bystolic.doc.
38. Id. (emphasis added).
39. See Maryland Heart Center, Heart Center Physician Biographies, http://www.umm.
edu/heart/biographies.htm#Saunders (last visited Jan. 06, 2010).
40. See U.S. Patent Application 20070014733 and U.S. Patent Application
20070014734, supra note 18.
41. See id.
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the larger patent. (The idea being that if a broader claim is challenged—
e.g. the use of nebivolol in a “human”—a narrower claim may survive—
e.g. the use of nebivolol in a person of “African descent”). If granted, the
patents also will provide a legally sanctioned basis for using race to
distinguish Bystolic in the marketplace. Thus, in 2008, on a list of the top
pharmaceutical advertisers in the country, Forest Laboratories moved up
from number seven to number two.42 The trade journal, Medical Marketing
and Media noted, Bystolic, at $8.4 million, was the most heavily advertised
drug in the country during the first half of 2008.43 As Forest Laboratories
rolls out Bystolic, reports of its race-specific efficacy serve as a critical
adjunct to its general advertising efforts as it seeks to gain a foothold in the
crowded beta-blocker market.
In the latest stage of nebivolol’s journey into race-specific marketing, Dr.
R. Preston Mason, a consultant to Forest Laboratories,44 led a study
comparing the effect of nebivolol in “Mexican Americans” to “non-Hispanic
Whites.”45 Comparing nebivolol against the beta-blocker, atenolol, the
study concluded that, “[t]reatment with nebivolol, but not atenolol,
enhanced both the expression and coupling efficiency of eNOS in Mexican
American endothelium.” 46 That is, race (or here, perhaps more accurately,
Mexican American/Hispanic ethnicity) is claimed to make a difference in
nebivolol efficacy, further distinguishing it from other beta-blockers on the
market.
Mason was also involved in the earlier African American study of
nebivolol.47 He is on the faculty of the Harvard Medical School-affiliated
Brigham and Women’s Hospital in Boston, Massachusetts, and also
President and Founder of Elucida Research LLC, a private biotechnology
firm, in Beverly, Massachusetts.48 He now also has a race-specific patent
application pending before the PTO titled, “Treatment of Cardiovascular
42. Eugene M. May, The Hits Keep on Coming, MED. MARKETING & MEDIA, Oct. 2008, at
57, 58 (listing the top spending pharmaceutical companies by advertising dollars).
43. Id. at 60.
44. theheart.org, Emerging Options for Hypertensive Patients with Osteoarthritis (Aug. 25,
2009), http://www.theheart.org/article/974377.do.
45. R.P. Mason et al., Nitric Oxide Bioavailability Is Lower in Endothelium of Healthy
Mexican American Donors as Compared to Non-Hispanic White Donors: Effect of Nebivolol,
Abstracts from Scientific Sessions 2007, 116 SUPPLEMENT TO CIRCULATION II-295, II-295
(2007).
46. Id.
47. See R. Preston Mason et al., Nebivolol Reduces Nitroxidative Stress and Restores
Nitric Oxide Bioavailability in Endothelium of Black Americans, 112 CIRCULATION 3795, 3795
(2005), available at http://circ.ahajournals.org/cgi/content/full/112/24/3795.
48. 2009 Cardiometabolic Health Congress, Distinguished Faculty, Biography: R. Preston
Mason, MBA, PhD, http://www.cardiometabolichealth.org/2009/bios/MasonRPreston.asp
(last visited Jan. 06, 2010).
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Disease in Mexican Americans Using Nebivolol.”49 Race and ethnicity are
thus evolving from categories of biomedical research into ways of
organizing the strategic development of patent portfolios. The potential
value of race and ethnicity for generating patents, in turn, provides
incentives for designing and implementing race-specific clinical trials.
III. WARFARIN, RACE, AND THE BUSINESS OF PHARMACODIAGNOSTICS
Closely related to, but distinct from pharmacogenomic drug
development is the field of pharmacodiagnostics—the use of genetic testing
to identify specific genetic variations that affect individual drug response.50
Pharmacodiagnostics is thus a critical component of the drive toward
genetically informed personalized medicine. Being focused on specific
genes, one might think that race would be even less relevant in this field
than in drug development. Yet, here also, race has persisted, and even
thrived. Similar to the case of Bystolic, some manufacturers of genetic tests
have found race to be a useful tool for differentiating their products in a
crowded marketplace. A prominent example involves tests developed to
identify specific genetic variations recently discovered to have a significant
effect on individual response to the widely prescribed blood-thinning drug
warfarin (marketed by Bristol-Meyers Squib under the trade name
Coumadin®).51
Warfarin, an anticoagulant, is among the most widely prescribed drugs
in modern medicine.52 In 2004, more than thirty million prescriptions were
written for the drug in the United States alone.53 Sales of warfarin in the
U.S. were approximately $500 million in 2002.54 “There was a 1.5-fold
increase in warfarin prescriptions between 1999 and 2005,”55 perhaps
reflecting the demographic shift toward an aging population, which is
typically a primary target of warfarin therapy. It is commonly prescribed to
patients who are at risk of developing blood clots, such as persons with

49. Treatment of Cardiovascular Disease in Mexican Americans Using Nebivolol, U.S.
Patent Application No. 20090030071 (filed July 15, 2008).
50. See H. Ngow, supra note 20, at 642-43.
51. See, e.g., PGXL Laboratories, Warfarin, (describing PGXL Laboratories’
Pharmacogenetic warfarin test) http://www.pgxlab.com/clinician/warfarin.php (last visited Jan.
06, 2010).
52. Nanogen, Pharmacogenetics and Warfarin Therapy, NEXT GENERATION
PHARMACEUTICALS, Jan. 2007, http://www.ngpharma.com/article/Pharmacogenetics-andwarfarin-therapy/.
53. Int’l Warfarin Pharmacogenetics Consortium, Estimation of the Warfarin Dose with
Clinical and Pharmacogenetic Data, 360 NEW ENG. J. MED. 753, 754 (2009).
54. Nanogen, supra note 52.
55. Myong-Jin Kim et al., A Regulatory Science Perspective on Warfarin Therapy: A
Pharmacogenetic Opportunity, 49 J. CLINICAL PHARMACOLOGY 138, 139 (2009).
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atrial fibrillation (a type of abnormal heart beat), recurrent strokes, deep
venous thrombosis, pulmonary embolism, or those who have received heart
valve replacements.56 It is difficult to calibrate the correct dose for an
individual patient because it has a narrow therapeutic window of efficacy
and a wide-range of inter-individual variability in response.57 Finding a
correct dosage can be a delicate matter, involving the gradual upward
titration of an initially low dose with regular monitoring of the coagulation
rate using the “international normalized ratio” or INR (INR compares the
blood’s clotting ability at a given moment to a standardized measure) and
adjusting the dosage until the appropriate rate of coagulation is obtained.58
Too much warfarin places a patient at risk of developing a potentially fatal
hemorrhage, while too little may increase the risk of blood clots and
stroke.59 The complexity of warfarin dosing is indicated by the fact that
warfarin is the second most common drug (after insulin) implicated in
emergency room visits, having caused 1,234 emergency room cases in
2004.60 Further, it is estimated that there are actually over 43,000 adverse
drug events related to warfarin each year.61
In the past decade, great strides have been made toward identifying
specific genetic variations that have significant impacts on individual
response to warfarin. Researchers have identified genes responsible for
producing the enzymes that metabolize warfarin (enzymes that break
warfarin down and destroy its anticoagulant activity).62 In particular, specific
polymorphisms in the CYP2C9 gene and VKORC1 gene have been
identified as accounting for thirty to fifty percent of variation in individual
warfarin response.63 CYP2C9 affects pharmacokinetics—or what a body
does to a drug.64 People with certain CYP2C9 alleles that metabolize

56. See id. at 138.
57. Id.
58. See Daly, supra note 19, at 10.1.
59. U.S. Food & Drug Admin., Critical Path Initiative - Warfarin Dosing (interviewing FDA
staff involved in pharmacogenetics of warfarin therapy), http://www.fda.gov/ScienceResearch/
SpecialTopics/CriticalPathInitiative/FacesBehindCriticalPath/ucm077473.htm (last visited Dec.
28, 2009). See Daly, supra note 19, at 10.1-10.4.
60. Daniel S. Budnitz et al., National Surveillance of Emergency Department Visits for
Outpatient Adverse Drug Events, 296 JAMA 1858, 1864 (2006).
61. Id.
62. See Anna Wilde Mathews, In Milestone, FDA Pushes Genetic Tests Tied to Drug, WALL
ST. J., Aug. 16, 2007, at A1, available at http://mednews.wustl.edu/clip/page/normal/
15608.html.
63. M. Teichert et al., Genotypes Associated with Reduced Activity of VKORC1 and

CYP2C9 and Their Modification of Acenocoumarol Anticoagulation During the Initial
Treatment Period, 85 CLINICAL PHARMACOLOGY & THERAPEUTICS 379, 379 (2009).
64. See Alan HB Wu et al., Dosing Algorithm for Warfarin Using CYP2C9 and VKORC1
Genotyping from a Multi-Ethnic Population: Comparison with Other Equations, 9
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warfarin more slowly than average would need a lower dose of warfarin.65
VKORC1, in contrast, involves pharmacodynamics, 66 or “what a drug does
to a body . . . .”67 Warfarin works, in part, by suppressing the production of
vitamin K, which is vital to blood clotting.68 Individuals with certain
VKORC1 alleles might also need a lower dose of warfarin.69 Carriers of two
CYP2C9 alleles commonly referred to as *1, also known as the “wild type”
or standard type, “are extensive metabolizers of warfarin.”70 The two
common relevant CYP2C9 variants are referred to as CYP2C9*2 and *3.71
The most common relevant VKORC1 variant is referred to as VKORC1
3673 G>A (or -1639 G>A).72 These variants have become particular
targets for genetic testing.
With the proliferation of genetic data one might think that race would
cease to play a significant role in studies of warfarin response. Yet, as
genetic studies have proliferated, so has the use of race and related
categories to assess variable frequencies of particular polymorphisms in
specific population groups. Thus, numerous studies have observed that
some relevant CYP2C9 and VKORC1 alleles vary in frequency across
certain ethnic or racial groups.73 Usually these studies use such broad
categories as “Asian,” “Caucasian,” “Hispanic” or “African-American,”74
but some studies are more nation-specific, identifying allele frequencies and
response, for example, in Swedes, Koreans, Iranians, Japanese, and
Israelis.75 Ironically, there seems to have been an increase in such racial,
See generally Milo Gibaldi & Gerhard Levy,
Pharmacokinetics in Clinical Practice: I. Concepts, 235 JAMA 1864, 1864 (1976) (defining
PHARMACOGENOMICS 169, 176 (2008).

pharmacokinetics as being “concerned with the study and characterization of the time course
of drug absorption, distribution, metabolism, and excretion, and with the relationship of these
processes to the intensity and time course of therapeutic and adverse effects of drugs”).
65. See Kim, supra note 55, at 140.
66. See Wu, supra note 64, at 176.
67. See Merck, The Merck Manuals Online Medical Library, Introduction:
Pharmacodynamics (2007) (defining pharmacodynamics), http://www.merck.com/mmpe/sec
20/ch304/ch304a.html.
68. See Mathews, supra note 62. See also Wu, supra note 64, at 169.
69. Wu, supra note 64, at 169.
70. Kim, supra note 55, at 140.
71. Julie A. Johnson, Ethnic Differences in Cardiovascular Drug Response: Potential
Contribution of Pharmacogenetics, 118 CIRCULATION 1383, 1384 (2008).
72. Id.
73. See, e.g., id. at 1384-85; Wu, supra note 64, at 169.
74. See, e.g., Wu, supra note 64, at 169.
75. See, e.g., Hyun-Jung Cho et al., Factors Affecting the Interindividual Variability of
Warfarin Dose Requirement in Adult Korean Patients, 8 PHARMACOGENOMICS 329, 329
(2007); P. Ghadam et al., VKORC1 Gene Analysis in an Iranian Warfarin Resistant Patient, 8
J. BIOLOGICAL SCI. 691, 691 (2008); Kenji Nakai et al., Ethnic Differences in the VKORC1

Gene Polymorphism and an Association with Warfarin Dosage Requirements in
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ethnic, or nation-specific studies of allele frequencies in recent years as the
significance of specific genetic variations has been more fully elaborated
and characterized.
IV. LABELS, TESTS, AND “ETHNIC” PRODUCT DIFFERENTIATION
By August 2007, enough data on the genetics of warfarin response had
been published to convince the FDA to authorize a labeling change to
Coumadin to explain how users’ genetics may affect their responses to the
drug.76 In a conference call announcing the change, the FDA’s Lawrence
Lesko noted that, “this marks the first time that such pharmacogenomic
information has been included in a widely used drug . . . . This means that
personalized medicine is no longer an abstract concept, but has moved into
the mainstream, where it is recognized as a factor in a product used by
millions of Americans.”77 Or, as an article in the journal Medical Marketing
& Media enthused, “The FDA rang in the era of personalized medicine with
a labeling change on blood thinner warfarin cautioning that patients with
either of two genetic variations might respond differently to the drug.”78
Significantly, news reports of the FDA-mandated label change also
noted some of its regulatory, legal, and commercial implications. First,
Jane Woodcock, deputy commissioner and chief medical officer of the FDA,
emphasized that the labeling update was “not a directive to doctors to use
genetic tests for warfarin therapy” since current clinical studies do not
definitively support such a recommendation.79 This caution was warranted
given the fact that no prospective clinical trials had yet been conducted
comparing the outcomes of using genetic tests to guide warfarin dosing as
compared to existing practices.80 It reflects well-established understandings
of the FDA’s role of regulating drugs and not the practice of medicine.

Cardiovascular Surgery Patients, 8 PHARMACOGENOMICS 713, 713 (2007) (assessing allele
frequencies of Japanese and Israeli populations); Fumihiko Takeuchi et al., A Genome-Wide
Association Study Confirms VKORC1, CYP2C9, and CYP4F2 as Principal Genetic
Determinants of Warfarin Dose, PLOS GENETICS, Mar. 2009, at 1 (study identifying allele
frequencies
in
Swedish
patients),
available
at
http://www.plosgenetics.org/article/info:doi/10.1371/journal. pgen.1000433.
76. Turna Ray, FDA Updates Warfarin to Explain Genetic Links to Response; Says Change
Not Meant As ‘Directive’ for Doctors, GENOMEWEB DAILY NEWS, Aug. 16, 2007,
http://www.genomeweb.com/fda-updates-warfarin-label-explain-genetic-links-response-sayschange-not-meant-.
77. Id.
78. Matthew Arnold, Warfarin Label Change Advises on Genetic Factors, MED.
MARKETING & MEDIA, Aug. 16, 2007, http://www.mmm-online.com/Warfarin-label-changeadvises-on-genetic-factors/article/30045/.
79. Ray, supra note 76.
80. See Mathews, supra note 62.
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Second, it also reflects a concern involving potential legal claims of
malpractice liability. A report in the Wall Street Journal noted that prior to
the labeling change, a medical group called the Anticoagulation Forum
wrote a letter to Dr. Lesko warning that doctors might place too much
reliance on the genetic tests, and subsequently fail to monitor their patients
effectively.81 The Anticoagulation Forum worries that some doctors might
even hold off in starting a patient on warfarin until the doctors have the
results of the test in hand.82 “The group asked that any new label ‘reflect
the uncertainty’ so doctors wouldn’t be held liable in court for failing to do
the tests.”83 Third, even without a directive to test, large insurers like Aetna
consider such labeling changes when deciding whether to reimburse for a
genetic test.84 The labeling change, thus, had significant implications for
the growing industry of pharmacodiagnostics. Indeed, since the labeling
change, a number of companies have petitioned the FDA for approval of
diagnostic kits that test for a variety of CYP2C9 and VKORC1
polymorphisms related to warfarin response.85
Numerous companies offer one form of genetic testing or another
related to warfarin response.86 These range from smaller dedicated
diagnostic companies such as Autogenomics, Nanosphere, and
Osmetech,87 to new, large, full-service direct-to-consumer genomics
companies such as 23andMe, DNA Direct, and deCODE genetics.88 These
latter direct-to-consumer companies offer so-called “home brew” tests that
do not require specific FDA approval to be offered to the public.89
Additional companies offering such tests include ARUP Laboratories,
Laboratory Corporation of America, Mayo Medical Laboratories, Kimball
Genetics, PGXL Laboratories, Clinical Data, and Genelex.90

Mathews, supra note 62.
Id.
Id.
Ray, supra note 76.
See Ray, supra note 21.
Id.
Id.
Turna Ray, 23andMe Begins Reporting Three SNPs for Warfarin Sensitivity; Plans to
Study Others, PHARMACOGENOMICS REP., Apr. 1, 2009, http://www.genomeweb.com/dxpgx/
23andme-begins-reporting-three-snps-warfarin-sensitivity-plans-study-others.
89. GenomeWeb News, CombiMatrix Forms Molecular Dx Unit to Perform Home-Brew
Tests; Eyes Eventual FDA Clearance, GENOMEWEB DAILY NEWS, May 10, 2005,
http://www.genomeweb.com/combimatrix-forms-molecular-dx-unit-perform-home-brew-testseyes-eventual-fda-cl. See also Genetics & Public Policy Center, Who Regulates Genetic Tests?
(Feb. 27, 2006) (discussing federal regulation of genetic testing), http://www.dnapolicy.org/
policy.issue.php?action=detail&issuebrief_id=10.
90. Ray, supra note 21.
81.
82.
83.
84.
85.
86.
87.
88.
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In this crowded market, one basic way for a company to differentiate its
product is to obtain FDA approval for its particular test, thereby certifying its
clinical validity.91 A number of companies have obtained such approval,
including Autogenomics, Nanosphere, Paragon Dx, and Osmetech.92
Beyond this, companies are also highlighting their ability to provide
distinctive services such as fast turnaround time, additional consultation, or
even help with processing claims. 93 Finally, because there are numerous
alleles, both of CYP2C9 and VKORC1, for which it is possible to test, some
companies distinguish their tests by allele.94 The most commonly tested
alleles are CYP2C9*2 and *3, and VKORC1 mutations at the -1639G>A
positions.95 Nanosphere, for example, distinguishes its test in part by noting
that it also tests at the VKORC1 1173C>T positions.96
In the realm of allelic product differentiation, AutoGenomics has come
up with race, or as it says “ethnicity,” as a means to make its product stand
out in the crowd.97 It does this by looking at some of the less common
CYP2C9 and VKORC1 alleles and evaluates how their frequencies vary
across ethnic groups.98 As one news article on competition in the warfarin
gene-testing market put it:
AutoGenomics boasts that its INFINITI assay detects 15 2C9 and VKORC1
variants, more than any other company in the market. Most other warfarin
sensitivity assays look for the 2C9 *2 and *3, and the 3673 (-1639G>A)
VKORC polymorphisms.
Among the 15 variants the INFINITI assay detects, several polymorphisms
will be specific to particular ethnicities – such as the *4 variant identified
exclusively among Japanese people and the 8773 SNPs in VKORC1 found
in 21 percent of African Americans.

91. See id.
92. CENTERS FOR MEDICARE & MEDICAID SERV., PROPOSED DECISION MEMO FOR
PHARMACOGENOMIC TESTING FOR WARFARIN RESPONSE (CAG-00400N) (2009),
https://www.cms.hhs.gov/mcd/viewdraftdecisionmemo.asp?from2=viewdraftdecisionmemo.a
sp&id=224&.
93. Ray, supra note 21.
94. See Turna Ray, AutoGenomics’ Warfarin Test Wins FDA OK; Gauges Variants
Competitors Don’t, PHARMACOGENOMICS REP., Jan. 30, 2008, http://www.genomeweb.com/
dxpgx/autogenomics%E2%80%99-warfarin-test-wins-fda-ok-gauges-variants-competitorsdon%E2%80%99t.
95. Id.
96. Ray, supra note 21.
97. See id.
98. Id.
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Therefore, in marketing its test, AutoGenomics will likely specifically target
certain ethnic groups, in addition to widely promoting it for the 200,000 to
500,000 patients who get initiated on warfarin each year.99

AutoGenomics is a privately held company, based in Carlsbad,
California.100 Its mission is “to empower clinical laboratories with an
automated cost effective solution to perform molecular testing that will
significantly enhance work flow, cost efficiency, quicker turn-around time
and result with enhanced patient care.”101 AutoGenomics offers an array of
genetic tests on its website. Many are currently for research use only (RUO),
meaning they have not obtained FDA approval.102 It currently markets four
FDA-approved tests, including a Warfarin Assay product.103 This particular
assay, however, only covers the common CYP2C9*2 and *3 variations, and
the VKORC1 3673 (-1639G>A) variant.104 The assay is not marketed with
explicit reference to ethnicity.105
AutoGenomics also has an extended “Warfarin XP” assay which tests for
six different CYP2C9 variants and eight VKORC1 variants, but it is not yet
FDA approved, so it is still only marketed for research use.106 Nonetheless,
while its application for FDA approval of its basic warfarin gene test was still
pending, the AutoGenomics website was rife with information on differing
allele frequencies across ethnic groups and highlighted the Warfarin XP
assay’s distinctive abilities to test broadly across an array of ethnic
groups.107
One AutoGenomics webpage, for example, ran with the title caption,
“Warfarin XP: Enhanced Ethnic Characterization.”108 The expanded panel

99. Id. (emphasis added).
100. AutoGenomics, About Us, http://www.autogenomics.com/1/aboutUs.php (last visited
Jan. 06, 2010).
101. Id.
102. AutoGenomics, INFINITI® Test Menu (RUO), http://www.autogenomics.com/1/RUO_
main.php (last visited Dec. 28, 2009).
103. Id.
104. AutoGenomics, INFINITI® Warfarin Assay (IVD), http://www.autogenomics.com/1/
pharma_warfarinassay.php (last visited Jan. 06, 2010).
105. See id.
106. AutoGenomics, INFINITI™ CYP450 2C9-VKORC1, http://www.autogenomics.com/1/
pharma_2C9.php (last visited Jan. 06, 2010).
107. AutoGenomics, Home Page, http://www.autogenomics.com/1/ (last visited Jan. 06,
2010). After FDA approval was obtained AutoGenomics has updated its website and no
longer contains pre-approval information. See Ray, supra note 21 (explaining that before
FDA approval, AutoGenomics claimed INFINITI assay detected several polymorphisms across
ethnicities and would likely market the assay towards specific ethnic groups).
108. AutoGenomics, Warfarin XP: Enhanced Ethnic Characterization, http://www.auto
genomics.com (last visited July 14, 2008) (no longer available); see also AutoGenomics, Data
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test explicitly linked genetics to ethnicity. In a section discussing the “clinical
relevance” of the test, AutoGenomics discusses the frequency of certain less
common variants directly in terms of frequency in “Japanese,” “AfricanAmericans,” and “Caucasians.”109 Here is a clear example of when specific
alleles are identified and testable yet a company still uses race to
characterize the product. Yet, why would AutoGenomics continue to use
race if the gene has already been identified? Certainly it is the gene
variants, not race, which make the difference in clinical response. It
becomes evident that AutoGenomics is layering ethnicity onto its more basic
Warfarin Assay product in order to differentiate its test and expand its
market share. Most companies, including AutoGenomics, will test for the
three most common genetic variants affecting warfarin response.110
Ethnicity here provides AutoGenomics the basis for offering a second test
that covers those three common variants plus an additional eleven
variants.111 The ethnicities identified also conveniently correspond to major
racial groups—Asian (assuming Japanese comes to be taken as a stand-in
for “Asian”), African (or African American), European (Caucasian). Who
might want this test then? Apparently everyone in Japan, the United States
(with the exception of Native Americans), and Europe—i.e. the world’s
major medical markets—comprise the targeted population. It might seem
at first blush that developing a test for less common alleles might narrow
one’s market, but when bundled with the test for common alleles and
layered with racial identities, it becomes a potential means to capture
greater market share.
The salience of race in AutoGenomics’ marketing strategy is most
evident in a 2008 PowerPoint presentation from its website, titled “Infiniti™
Warfarin XP: Because Ethnic Diversity Matters When Dosing With Warfarin.”
112
The presentation begins with a slide noting the importance of the recent
FDA re-labeling of warfarin for genetic data.113 It then discusses the
variation across race of the particular CYP2C9 and VKORC1 alleles for
which it tests, noting that its product is “THE ONLY TEST AVAILABLE THAT
INCLUDES ALL RELEVANT VARIANTS!”114 The inevitable conclusion is that
“[d]etecting 2C9 variants in addition to [the common] *2, *3 is essential for
Sheet, http://www.autogenomics.com/1/DataSheets/warfarinxp/dosingAlgorithms.pdf (last
visited Jan. 06, 2010).
109. AutoGenomics, 2C9-VKORC1 Pharmacogenetics, http://www.buhlmannlabs.ch/files/
documents/molecular/autogenomics/flyer_2c9-vkorc1.pdf (last visited Jan. 06, 2010).
110. Ray, supra note 94.
111. Id.
112. AutoGenomics, Infiniti™ Warfarin XP: Because Ethnic Diversity Matters When Dosing
with Warfarin 1 (on file with author).
113. Id. at 2.
114. Id. at 23.
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a broader identification of high risk warfarin metabolizers in several ethnic
groups.” 115 The emphasis here is on the need for an expanded panel
testing for more variants. Ethnicity provides a rationale for offering an
expanded test panel that differentiates the AutoGenomics test from others
on the market.
One of AutoGenomics’ most explicit uses of race to differentiate its
product occurs in the following slide:116

According to this slide, tests other than AutoGenomics Infiniti platform
would miss relevant genetic variants in “virtually ALL non-caucasian [sic]
patients; Asian, African American, Chinese, Japanese, Hispanic, etc., would
be missed using a panel limited to these variants.”117 The slant here is quite
striking; it makes racial and ethnic identification appear to be essential to
finding relevant genetic variants. In fact, the common *2, *3, and 1173
variants mentioned in this slide occur in all of these groups at differing
frequencies.118 The only possible way to make sense of its claim about
“missing” “non-Caucasians” is to assume it is referring to the patients with
the rarer alleles who would be missed by products that do not test for them.

115.
116.
117.
118.

Id. at 24.
Id. at 28.
Id.
See Johnson, supra note 71, at 1384.
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In developing its test, therefore, AutoGenomics is not just looking for genes;
it is looking for racial and ethnic groups to whom it can market its product.
This is also evident in the slide’s reference to variations “specific” to Asians
and African Americans. (Ironically, the reference to African Americanspecific variants also are said to be of significance to “Caucasians”).
AutoGenomics is attempting to translate racially identified gene frequencies
into racially identified market share. In this case, finding specific genes has
not led researchers to leave race behind. To the contrary, it has led to the
rise of new ways to exploit race in the biomedical marketplace.
Marketing based upon race also provides rationale for its commercial
viability. If AutoGenomics simply tested for rare alleles, e.g. CYP2C9 *5, *6
or *11, it might have difficulty gaining acceptance in the market against
products that tested for the most common significant variants. Simply
adding an array of rare alleles that only marginally increases the odds of
finding a significant genetic variation could easily make AutoGenomics’ test
appear needlessly complex. Yet, by tying rare alleles to specific ethnic or
racial groups, AutoGenomics provides a hook to draw in potential
consumers. You might not know whether you have a rare allele but you do
know if you are black, white or Asian. A product that says it tests for a rare
allele that is found primarily in the individual’s racial or ethnic group is one
he or she may choose despite its rarity. AutoGenomics thus uses race not to
identify alleles but rather to induce consumers to identify their own race or
ethnicity (and hence themselves) with certain alleles. AutoGenomics frames
the test so that African, Asian, or European race becomes identified in the
consumer’s mind with allele frequency. Beyond this, for the product actually
to succeed in the market place, biomedical professionals and insurance
companies must similarly identify race with genetics in warfarin response.
Through its product development and marketing strategies, AutoGenomics
is not only selling a pharmacogenomics assay, it is producing a conception
of race as genetic.
Ironically, following its 2008 approval of AutoGenomics’ basic warfarin
assay that tested only for the three most common CYP2C9 and VKORC1
variants, the FDA required AutoGenomics to remove all material of “clinical
relevance” associated with its various RUO assays from its website.119 The
Warfarin XP expanded panel is not yet FDA approved, i.e. it is for “Research
Use Only.”120 All of AutoGenomics’ references to race appeared under
“Clinical Relevance” headings for Warfarin XP and have since been
removed from the website.
Similarly, the “Because Ethnic Diversity
Matters . . .” presentation has also been removed from the website.
119. Email from Anand Vairavan, Marketing Manager and personalized Medicine
Specialist for AutoGenomics, (May 20, 2009) (on file with author).
120. AutoGenomics, supra note 106.
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Nonetheless, Anand Viaravan, Marketing Manager and Personalized
Medicine Specialist for AutoGenomics, insists that “we still absolutely believe
that Ethnic Diversity Matters when developing genetic tests to help with
Warfarin dosing.”121 Indeed, he notes that “we still do offer this assay and
sell more of the Expanded Panel assay as opposed to the [FDA approved]
IVD assay.”122
Here, regulatory approval extracted a trade-off among tactics for
product differentiation. On the one hand, AutoGenomics gained the
legitimacy and distinction conferred by the FDA approval. On the other
hand, it has since been forced to downplay the racial aspect of the
Expanded Assay at least until it gets FDA approval for that test as well.
Nonetheless, AutoGenomics’ commitment to racialized marketing of its
product remains clear and the expanded assay continues to be a more
profitable test. Indeed, AutoGenomics has licensed the technology to
several companies in Europe, one of which, the Swiss Company Buhlmann
Laboratories, AG, continues to post AutoGenomics’ slides on its website
describing the expanded assay with race-specific information.123
AutoGenomics thus is working to minimize the impact of this trade-off and
maintain its commitment to producing and capturing a racialized market.
There is an additional and deeper irony embedded in AutoGenomics’
marketing strategy. At first glance, the use of race to help target therapies,
whether for warfarin or for BiDil, may appear to be a means to redress
historically race-based inequities in the delivery of health care in the United
States. Certainly, taking account of the distinct needs and concerns of
historically disadvantaged minority communities is a laudable and worthy
goal. The Civil Rights Act of 1964, the Voting Rights Act of 1965, and the
Fair Housing Act of 1965 all took race into account in fashioning remedies
for historical race based inequities.124 In the realm of biology, however, the
use of race becomes far more problematic than in other areas of past
discrimination such as employment, voting, or housing. As biologist Anne
Fausto-Sterling notes, “Only rather slowly has the medical community
realized that what appears at first to be an inclusive move—mandating
participation by racially and sexually distinguishable groups in drug and
other trials—might have a scorpion’s sting, diverting attention from
socioeconomic explanations of (and remedies for) health disparities.”125

121.
122.
123.
124.

Email from Anand Vairavan, supra note 119.

Id.

AutoGenomics, supra note 109.
See Eric K. Yamamoto et al., Dismantling Civil Rights: Multiracial Resistance and
Reconstruction, 31 CUMB. L. REV. 523, 530-31 (2001).
125. Anne Fausto-Sterling, Refashioning Race: DNA and the Politics of Health Care,
DIFFERENCES, Fall 2004, at 1, 3.
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How much more powerful might this dynamic prove when driven by
commercial considerations of developing a market niche for a biomedical
product?
V. RACE, COMMERCE, AND REGULATORY CLASH
Market differentiation is one type of commercial imperative driving the
use of race in biomedical research and product development. More
straightforward concerns for economy and efficiency may also be providing
further impetus for continuing to use race in the face of genetic discovery.
Such concerns are alluded to in a study by Yen-Revollo et al., which notes
that using race as a surrogate is also appealing “because personal
genotyping is cost prohibitive.” 126 Simply stated, it is cheaper to identify a
patient by race than by genotype. Beyond this, it turns out race can be
economically relevant not only as an alternative to genotyping but also as a
complement to it. Thus, for example, a 2008 policy statement on gene
testing for warfarin response issued by the American College of Medical
Genetics (ACMG) states:
CYP2C9*2 and *3 are found in the major racial groups, but with different
allelic frequencies. These alleles should be tested in all individuals. There
are also several rare alleles of CYP2C9 alleles that have different
frequencies in different ethnic populations, and some alleles are
preferentially found in only certain racial groups. Some CYP2C9 alleles,
such as CYP2C9 *5, *6, and *11, are preferentially found in Africandescendent populations at low allele frequencies, but are not found in
Asian-descendant populations. On the other hand, the rare CYP2C9 *4
polymorphism has only been reported in individuals from Asia. The
decision to test for polymorphisms other than CYP2C9 *2 and *3 should be
based on the populations being tested by a laboratory and the capability to
make patient management decisions informed by these less-frequently
encountered alleles.127

Race is front and center here right alongside specific genetic variation.
Given the nature of genetic variation, however, it will always be possible to
find certain genetic variations that occur at differing frequencies across
racial groups.128 For example, studies of a particular VKORC1 variant have
126. Jane L. Yen-Revollo et al., Race Does Not Explain Genetic Heterogeneity in
Pharmacogenomic Pathways, 9 PHARMACOGENOMICS 1639, 1643 (2008).
127. David A. Flockhart et al., Pharmacogenetic Testing of CYP2C9 and VKORC1 Alleles
for Warfarin, 10 GENETICS MED. 139, 144 (2008) (emphasis added).
128. As sociologist Troy Duster has noted: “It is possible to make arbitrary groupings of
populations (geographic, linguistic, self-identified by faith, identified by others by
physiognomy, etc.) and still find statistically significant allelic variations between those
groupings. For example, we could examine all the people in Chicago, and all those in Los
Angeles, and find statistically significant differences in allele frequency at some loci. Of
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found a range of frequencies in European populations from 39% in
“Swedish” to 52% in “Spanish.”129 One comprehensive review article found
frequency variation for having at least one CYP2C*2 allele in different
“Caucasian” populations ranging from 0.9% to 20.4%, and a range for
“Africans” from 0.0% to 8.7%.130 On one hand, there certainly is a
difference in frequency between Africans and Caucasians. On the other
hand, there is also significant overlap, and the overall variation within the
Caucasian group seems to dwarf that between Africans and Caucasians.
The question is which differences the researchers and product developers
choose to make matter and how.
A sense of how these choices are made is provided by an examination
of the studies cited by the ACMG report to support its recommendation to
take race into account. Thus, to support its assertion that “[s]ome CYP2C9
alleles, such as CYP2C9 *5, *6, and *11, are preferentially found in
African-descendent populations at low allele frequencies, but are not found
in Asian-descendant populations,” 131 the report cites an article by Guyong
Tai et al., “In-Vitro and In-Vivo Effects of the CYP2C9*11 Polymorphism on
Warfarin Metabolism and Dose.”132 As is evident from the title, this study
discusses only the CYP2C9*11 polymorphism and says nothing about
frequencies for the *5 and *6 alleles.133 Moreover, this was a study of 303
“Caucasians” and 101 “African-Americans;” it says nothing about allele
frequencies in Asian populations.134 Additionally, to support its assertion
that “the rare CYP2C9 *4 polymorphism has been found only in individuals
from Asia,”135 the ACMG report cites an article titled, “A Case Report of a
Patient CarryingCYP2C9*3/4 Genotype with Extremely Low Warfarin Dose
Requirement.”136 As is evident again from the title, this study was a case

course, at many loci, even most loci, we would not find statistically significant differences.”
Troy Duster, Buried Alive: The Concept of Race in Science, in GENETIC NATURE/CULTURE:
ANTHROPOLOGY AND SCIENCE BEYOND THE TWO-CULTURE DIVIDE 258, 265 (Alan H. Goodman
et al. eds., 2003).
129. Pharmacogenomics Knowledge Base, Important Variant Information for VKORC1
(Oct. 30, 2008), http://www.pharmgkb.org/search/annotatedGene/vkorc1/variant.jsp.
130. Craig R. Lee, Joyce A. Goldstein & John A. Pieper, Cytochrome P450 2C9
Polymorphisms: A Comprehensive Review of the In-Vitro and Human Data, 12
PHARMACOGENETICS 251, 252 (2002).
131. Flockhart et al., supra note 127, at 144.
132. Guoying Tai et al., In-Vitro and In-Vivo Effects of the CYP2C9*11 Polymorphism on
Warfarin Metabolism and Dose, 15 PHARMACOGENETICS & GENOMICS 475, 475 (2005).
133. See id.
134. See id. at 476.
135. Flockhart et al., supra note 127, at 144.
136. Soo-Youn Lee et al., A Case Report of a Patient Carrying CYP2C9*3/4 Genotype
with Extremely Low Warfarin Dose Requirement, 22 J. KOREAN MED. SCI. 557, 557 (2007).
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report of a single Korean patient.137 The report itself notes, “This is the first
report of a Korean patient with the CYP2C9*3/*4 showing warfarin
intolerance. The CYP2C9*4 allele including 1076T>C (Ile359Thr) has
been reported in only one Japanese subject.”138 Thus, the ACMG has taken
a report of one Korean individual that also cites one additional Japanese
subject and expanded into a technically accurate, but highly misleading,
assertion that this allele is only found in “individuals from Asia.” There may
well be studies that provide better support for the ACMG’s assertions, but
the studies ACMG cites certainly are not sufficient. They only casually add
to an accumulating sort of folk wisdom or common sense in the medical
community that promotes the continued relevance of race alongside the
development of specific genetic information.
The basis for making the choice to frame allele frequency data in terms
of race takes on a distinctly economic feel when considered in light of the
statement’s overall purpose of identifying which groups should get which
tests. In the ACMG report, race becomes relevant here at the margins,
where allele frequencies are low and variable across racially defined
population groups.139 The ACMG, in effect, suggests using race as a
screening mechanism to determine which individuals should get which
genetic tests; yet, multiplex assays such as those offered by AutoGenomics
(not to mention those now being offered by such genetic testing behemoths
as 23andMe) are currently able to test efficiently for a range of alleles at
once.140 The only apparent reason remaining for preferentially assigning
tests by race therefore appears to be economic, rather than scientific,
efficiency. If testing for more alleles costs more, then race may be used to
perform a sort of economic triage to focus on those for whom the test is
most likely to produce a useful result.
Lawrence Lesko and other senior FDA officials have echoed the logic of
the ACMG’s report, stating, for example, that:
The type of genomic data (e.g., which alleles, what genotypes) that needs to
be evaluated, and when, is one of the critical issues in drug development
and regulatory review. In some cases, consideration of racial/ethnic
differences in the distribution of various alleles with no or reduced metabolic
activity in the evaluation of dose-response relationships is important.141

137. See id.
138. Id. at 558 (italics in original).
139. See Flockhart et al., supra note 127, at 144.
140. See, e.g., AUTOGENOMICS, INFINITITM WARFARIN ASSAY (2C9 & VKORC1 MULTIPLEX
ASSAY), 3 (2008), available at http://www.autogenomics.com/1/pdf/warfarinAssayPackage_
Insert.pdf.
141. Shiew-Mei Huang et al., Application of Pharmacogenomics in Clinical Pharmacology,
16 TOXICOLOGY MECHANISMS & METHODS 89, 93 (2006) (internal citations omitted).
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The article goes on to specify CYP2C9 as one of the “recommended
polymorphic alleles to measure in specific population groups.”142 These
groups, not surprisingly, are racialized as “Caucasians,” “African
Americans,” and “Asian Americans.”143 For the FDA, then, race remains
not only a legitimate but a “critical factor” in evaluating drug dose
response—again, even as specific genes are being identified.144 In this
conceptualization of the promise of pharmacogenomics, genes are not
replacing race, they are complementing race.
All of this brings us back to AutoGenomics and its marketing campaign
for its Warfarin XP assay built around the proposition that “Ethnic Diversity
Matters.”145 The commercial value of this product is intimately tied to the
statements of biomedical professionals, such as the ACMG, and federal
regulators, such as Lesko at the FDA. Research, regulation, and commerce
are thus mutually implicated in producing an understanding of race as
relevant to pharmacogenomics and in constructing consumers and clinicians
who identify race with genetics when making medical decisions.
Research, regulation, and commerce, however, are not monolithic
phenomena. As already discussed above, there is ongoing debate among
researchers concerning the utility of race in pharmacogenomics. There is
also something of a regulatory clash between the FDA and the Centers for
Medicaid and Medicare Services (CMS) concerning warfarin testing. The
clash grows out of the 2007 FDA labeling change for warfarin that specified
the significance of specific alleles.146 The labeling change gave urgency to
efforts to develop viable genetic dosing algorithms and also provided a
great impetus to companies to develop and market genetic tests.147 A
recent market report from MarketResearch.com titled, “Pharmacodiagnostics
and Personalized Medicine 2009 (Markets, Challenges, Forecasts and Key
Players)” discusses warfarin and the economic significance of the FDA label
change at length.148

142. Id.
143. Id. at 94.
144. See id. at 96.
145. AutoGenomics, Infiniti™ Warfarin XP: Because Ethnic Diversity Matters When Dosing
with Warfarin, supra note 112.
146. Press Release, U.S. Food & Drug Admin., FDA Approves Updated Warfarin
(Coumadin) Prescribing Information (Aug. 16, 2007), http://www.fda.gov/NewsEvents/News
room/PressAnnouncements/2007/ucm108967.htm.
147. See Ray, supra note 21.
148. KALORAMA INFO., PHARMACODIAGNOSTICS AND PERSONALIZED MEDICINE 2009 (MARKETS,
CHALLENGES, FORECASTS AND KEY PLAYERS) (2009), available at http://www.market
research.com/product/display.asp?productid=2128157&xs=r&SID=95957877-45204494
4-524917733&curr=USD&kw=warfarin&view=abs.
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Gene tests for warfarin response average between $300 and $500 per
test.149 Paying for such tests obviously is central to the test’s commercial
success, and central to payment is the issue of insurance coverage. The
problem for companies that offer genetic tests is that the FDA
recommendation is based on the clinical validity of the tests while insurance
coverage tends to be based on considerations of clinical utility and related
concerns for cost-effectiveness.150
The clinical utility of genetic testing for warfarin dosing has not yet been
established to the satisfaction of numerous insurers. One article in the Wall
Street Journal noted that “major insurers such as Aetna Inc., WellPoint Inc.
and Cigna Corp.” do not cover the costs of such tests, possibly because
“[s]ome specialists say testing hasn’t been proved to reduce the risks of the
drug.” 151 Indeed, even such influential studies as that conducted by the
IWPC were retrospective and did not measure whether incorporating genetic
data into dosing algorithms materially reduced adverse drug events
(ADEs).152 As University of Washington professor, Ann Wittkowsky, said of
the FDA labeling decision, “It is fascinating science, but it is not yet ready for
prime time [sic].”153
Similarly, a 2008 report of the Secretary of Health and Human Services’
Advisory Committee on Genetics, Health and Society (SACGHS) titled
“Realizing the Potential of Pharmacogenomics: Opportunities and
Challenges” while referring to the use of CYP2C9 and VKORC1 testing to
guide warfarin dosage as an early application of pharmacogenomics,
nonetheless indicated that “much of the valuable information about PGx
[pharmacogenomics] is in the form of early scientific discoveries. Although
this information has the potential to be useful, its clinical utility is not yet well
understood.”154 Francis Collins, shortly after he stepped down as Director
of the National Human Genome Research Institute, stated his belief that
researchers still did not “have the right type of evidence ‘to enable a clear
statement to providers about whether this kind of genetic testing ought to be
done prospectively before trying to prescribe this drug with all of its

149. Ray, supra note 21.
150. Turna Ray, Personalized Rx Advocates Call on FDA, CMS to Align Standards After
CMS’ Restricted Coverage of PGx Warfarin Dosing, PHARMACOGENOMICS REP., May 20,
2009,
http://www.genomeweb.com/dxpgx/personalized-rx-advocates-call-evidenceguidelines-wake -cms-decision-restrict-co.
151. Mathews, supra note 62.
152. See Int’l Warfarin Pharmacogenetics Consortium, supra note 53, at 754.
153. Mathews, supra note 62.
154. DEPT. OF HEALTH & HUM. SERV., SECRETARY’S ADVISORY COMM. ON GENETICS, HEALTH &
SOCIETY, REALIZING THE POTENTIAL OF PHARMACOGENOMICS: OPPORTUNITIES AND CHALLENGES 1
(2008), available at http://oba.od.nih.gov/oba/SACGHS/reports/SACGHS_PGx_report.pdf.
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complications.’”155 Even the FDA’s own deputy commissioner and chief
medical officer, Janet Woodcock, noted that they would “have to wait for
outcomes data” before actually changing the label to mandate genetic
testing.156
So it was that in May 2009 that CMS announced its intention to deny
Medicare coverage for pharmacogenomic testing that aims to predict
warfarin responsiveness, stating that it “believes that the available evidence
does not demonstrate that [such testing] improves health outcomes in
Medicare beneficiaries.”157 CMS held out the possibility that coverage
might be granted in the future, but only for a prospective, randomized
clinical trial.158
In the January 2009 issue of the Annals of Internal Medicine, a timely
study was published questioning the cost-effectiveness of using
pharmacogenomics information in warfarin-dosing.159 Dr. Mark Eckman,
the lead author on the study, pointedly criticized a 2006 study conducted
jointly by the American Enterprise Institute and the Brookings Institution that
estimated an annual savings of $100 million to $2 billion from integrating
genetic testing into warfarin therapy,160 as “optimistic” in its assumptions.161
The AEI-Brookings report was actually conducted by FDA staff162 and had
been posted by the FDA to support the drive toward incorporating
pharmacogenomic data in drug submissions.163 It was also cited by

155. Matt Jones, Francis Collins Addresses State of Personalized Medicine, GENOMEWEB
DAILY NEWS, Jan. 30, 2009, http://www.genomeweb.com/dxpgx/francis-collins-addressesstate-personalized-medicine.
156. Ray, supra note 76.
157. CENTERS FOR MEDICARE & MEDICAID SERV., supra note 92.
158. Id.
159. Mark H. Eckman et al., Cost-Effectiveness of Using Pharmacogenetic Information in
Warfarin Dosing for Patients With Nonvalvular Atrial Fibrillation, 150 ANNALS INTERNAL MED.
73, 80 (2009).
160. Andrew McWilliam et al., Health Care Savings from Personalizing Medicine Using
Genetic Testing: The Case of Warfarin 3 (AEI-Brookings Joint Center for Reg. Stud., Working
Paper No. 06-23, 2006), available at http://aei-brookings.org/admin/authorpdfs/redirectsafely.php?fname=../pdffiles/WP06-23_topost.pdf.
161. Eckman et al., supra note 159, at 81. See also Monica R. McClain et al., A Rapid-

ACCE Review of CYP2C9 and VKORC1 Alleles Testing to Inform Warfarin Dosing in Adults at
Elevated Risk for Thrombotic Events to Avoid Serious Bleeding, 10 GENETICS MED. 89, 96
(2008) (criticizing the Brookings-AEI study, the author argues that “close examination of this
study reveals that the authors made several assumptions that may not be valid”).
162. McWilliam et al., supra note 160, at title page.
163. U.S. Food & Drug Admin., supra note 59.
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diagnostic companies, such as Iverson Genetic Diagnostics, Inc,164 and
Osmetech,165 to support the marketing of their products.
As one might expect, the CMS announcement was not well received by
companies offering genetic tests, especially given the fact that many private
payors follow CMS’s lead when determining whether to cover new
technologies.166 Ramanath Vairavan, senior VP of sales and marketing for
AutoGenomics, opined:
This illogical decision perhaps has been influenced by the lobbying of big
pharma, that in spite of numerous prospective studies and publications that
have clearly shown the benefit for genetic testing and the FDA relabeling of
the drug, CMS has succumbed into making a contradictory decision that will
certainly impact patient well being and the cost of healthcare. As a
manufacturer of the test we appeal to CMS to revisit this controversial
decision at the earliest.167

Vairavan’s concern regarding “big pharma” is notable and highlights
the fact that the pharmcogenomics industry is not monolithic. He is
apparently alluding to one of the great tensions at the heart of
pharmacogenomics: on one hand, it is understood as the wave of the
future, saving money and improving therapies. On the other hand, it
involves narrowing the market for a drug down to smaller and smaller
subgroups that show the best response.
One of the little known facts about blockbuster drugs is that they are
“typically effective in only forty to sixty percent of the patient population.”168
“By identifying true responders, pharmacogenomics also threatens to reduce
substantially (often by more than 50%) the potential consumer base for any
given drug.”169 One study of data from the Physician’s Desk Reference
found “[t]he percent of responders range from a low of 25% (oncology
products) to a high of 80% (Cox2 inhibitors), with the majority of drugs

164. Iverson Genetic Diagnostics, Inc., Warfarin Dosing Panel, http://www.iverson
genetics.com/ig_warfarin.html (last visited Jan. 06, 2010).
165. Press Release, Osmetech Molecular Diagnostics, Osmetech Licenses VKOR
Pharmacogenetic Marker for Warfarin Dosage Management from University of Washington
(Mar.
9,
2007),
available
at
http://www.osmetech.com/pdf/University_%20of_
Washington.pdf.
166. Turna Ray, CMS Denies Medicare Payment for Warfarin PGx Testing; Proposes
Limiting Coverage to Evidence Studies, PHARMACOGENOMICS REP., May 6, 2009,
http://www.genomeweb.com/dxpgx/cms-denies-medicare-payment-warfarin-pgx-testingproposes-limiting-coverage-evid.
167. Id.
168. DrugResearcher.com, Pharmacogenomics to Replace Pharma’s Business Model (Feb.
28, 2005), http://www.drugresearcher.com/content/view/print/76486.
169. Jonathan Kahn, Exploiting Race in Drug Development: BiDil’s Interim Model of
Pharmacogenomics, 38 SOC. STUD. SCI. 737, 742 (2008).
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having a responder rate of 50-60%.”170 The marketing model for genetic
tests ultimately depends on the ability to use genomics to identify which
subjects should get which drugs—i.e. to narrow the market for specific
drugs. The more pharmacodiagnostics companies are able to identify
genes that correspond with drug response, the greater will be the market for
their products. Each success for a company like AutoGenomics represents a
potential threat to big pharmaceutical companies marketing blockbuster
drugs to large, undifferentiated populations. Yet, one review of the
comments submitted to CMS before it announced its intentions found that
most of those opposing coverage (about eighteen percent of the total) were
“professional
organizations,
payors,
and
some
healthcare
providers . . . .”171 Those with the most immediate interest in the CMS
decisions appear to have been those with an immediate stake in the
payment for diagnostic tests.172
In the aftermath of the CMS decision, the Center for Medicine in the
Public Interest (CMPI) announced plans to develop a proposal outlining
areas where the FDA and CMS “can harmonize the way they evaluate
outcomes and guide treatment . . . .” 173 The CMPI is a conservative, freemarket oriented group associated with the Pacific Research Institute, a think
tank founded in 1979 whose stated vision is the promotion of “the principles
of individual freedom and personal responsibility [which], [t]he Institute
believes . . . are best encouraged through policies that emphasize a free
economy, private initiative, and limited government.”174 Since the plans
were announced, in part, as a response to the CMS decision, it seems
evident that the CMPI is casting the CMS as an impediment to product
development and hence the “harmonization” sought by the CMPI primarily
involves getting CMS to follow the more industry-friendly FDA in its attitude
toward genetic testing for warfarin.175
Hope is on the horizon for pharmacodiagnostic companies, however, as
prospective studies of the clinical utility of pharmagenomic dosing
algorithms are being designed and carried out. Prominent among these is a
trial known as COAG (Clarification of Optimal Anitcoagulation through

170. Penelope K. Manasco & Teresa E. Arledge, Drug Development Strategies, in
PHARMACOGENOMICS: SOCIAL, ETHICAL, AND CLINICAL DIMENSIONS 83, 85-86 (Mark A.
Rothstein ed., 2003).
171. Ray, supra note 166.
172. See id.
173. Ray, supra note 150.
174. Pacific Research Institute, About PRI, http://liberty.pacificresearch.org/about/
default.asp (last visited Jan. 06, 2010); Pacific Research Institute, Our Vision,
http://liberty.pacificresearch.org/about/our-vision (last visited Jan. 06, 2010).
175. See Ray, supra note 150.
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Genetics) directed by the National Heart, Lung, and Blood Institute.176 The
study will enroll 1,200 patients and cost nearly ten million dollars.177 In
February 2009, Raynard Kington, then acting Director of the NIH asserted,
“These efforts showcase NIH’s firm commitment to building a future of
personalized medicine—a future in which doctors will be able to prescribe
the optimal dosage of medicine for each patient right from the start.”178
Race does not seem to have played much of a role in the CMS decision
or subsequent debates about the merits of insurance coverage for genetic
tests. In the minutes of the February 2009 CMS meeting discussing genetic
testing, there is barely a mention of race or ethnicity.179 Race seems to be
much more important to FDA officials, such as Lawrence Lesko or Robert
Temple, who see it as a means to drive their agenda of pursuing
pharmacogenomic drug development, than it is to CMS officials (and
private insurers) who are focusing on the more contained, and less easily
racialized issues of clinical utility and cost-effectiveness. Indeed, warfarin is
front and center as a poster child for the FDA’s “Critical Path Initiative,” a
major effort begun in 2004 to “stimulate and facilitate a national effort to
modernize the sciences through which FDA-regulated products are
developed, evaluated, and manufactured.”180 The first of a series of
interviews posted on the FDA website to explore Critical Path projects
focused on warfarin.181 Race is useful to the FDA to the extent that it
furthers the progress of drugs such as warfarin towards the promise of
“personalized medicine,” and thus validates efforts such as the Critical Path
Initiative.182 CMS, in contrast, does not have any particular institutional
imperative to use race in making coverage determinations.
VI. THE CONTINUING VALUE OF RACE IN BIOTECHNOLOGY PATENTS
Race has re-entered the regulatory scene, however, in proceedings
before the PTO. Interestingly, it is not the genetic-testing companies, such

176. Turna Ray, NIH Launches Large Randomized Trial to Determine Utility of PGx-Based
Warfarin Dosing, PHARMACOGENOMICS REP., Feb. 18, 2009, http://www.genomeweb.com/
dxpgx/nih-launches-large-randomized-trial-determine-utility-pgx-based-warfarin-dosing.
177. Id.
178. Id.
179. See CENTERS FOR MEDICARE & MEDICAID SERV., MEDICARE EVIDENCE DEVELOPMENT &
COVERAGE ADVISORY COMM., MEETING MINUTES OF THE CENTERS FOR MEDICARE AND MEDICAID
SERVICES (2009).
180. Andrew C. Von Eschenbach, Comm’r of Food & Drugs, Critical Path Initiative:
Statement Before the Subcomm. on Agriculture, Rural Development, Food & Drug Admin., &
Related Agencies, S. Comm. on Appropriations (June 1, 2007) [hereinafter Critical Path
Initiative].
181. U.S. Food & Drug Admin., supra note 59.
182. Critical Path Initiative, supra note 180.
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as AutoGenomics, who are using race in their patents—their patents tend to
cover the technical specifications of their assay platforms (the actual
apparatus conducting the tests) with race being reserved for certain
marketing efforts. Rather, it is certain warfarin researchers themselves who
have introduced race into the realm of intellectual property. On December
21, 2005, Yuan-Tsong Chen, Hsiang-Yu Yuan, and Jin-Jer Chen filed a
patent application titled “Genetic Variants Predicting Warfarin Sensitivity.”183
The lead inventor, Yuan-Tsong Chen, is a Distinguished Research Fellow at
the Genomics Research Center and Director of the Institute of Biomedical
Sciences at the Academia Sinica in Taipei, Taiwan.184 He is also a Professor
in the Department of Genetics at Duke University in Durham, North
Carolina.185 The other inventors were also associated with the Academia
Sinica at the time of the application, and the patent rights have been
assigned to that institution.186 The Academia Sinica is a member of the
IWPC and is credited with supplying data to the dosing algorithm study
published so prominently in the New England Journal of Medicine in
February, 2009.187
The Abstract of the patent application states, “We discovered that a
polymorphism in the promoter of the VKORC1 gene is associated with
warfarin sensitivity. This polymorphism can explain both the inter-individual
and inter-ethnic differences in warfarin dose requirements.”188 The Claims
section includes the following:
1. A method of determining the dose range of a warfarin for a subject,
comprising investigating the sequence of the promoter of the VKORC1 gene
of the subject.”
*

*

*

9. The method of claim 1 wherein the subject is an Asian.
10. The method of claim 1 wherein the subject is a Caucasian.
11. The method of claim 1 wherein the subject is an African, African

American, or Hispanic.189

183. Genetic Variants Predicting Warfarin Sensitivity, U.S. Patent Application No.
20060166239 (filed Dec. 21, 2005).
184. Genomics
Research
Center,
Academia
Sinica,
Yuan-Tsong
Chen,
http://www.genomics.sinica.edu.tw/index.php?option=com_content&view=article&id=96&Ite
mid=211&lang=en (last visited Jan. 06, 2010).
185. Id.
186. Genetic Variants Predicting Warfarin Sensitivity, supra note 183.
187. Int’l Warfarin Pharmacogenetics Consortium, supra note 53, at 753-54, 763.
188. Genetic Variants Predicting Warfarin Sensitivity, supra note 183 (emphasis added).
189. Id. (emphasis added).
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The mention of race in the Claims section is particularly significant
because the claims specify the legally operative scope of the patent, defining
the formal legal “metes and bounds” of the territory covered by an
invention.190 The force and authority of the United States government is thus
conscripted into legitimating the use of race in relation to genetics in a
manner that implies that race itself is genetic. The basis for making such
race-specific claims is found in studies of allele frequencies that vary across
population groups. Such variation is here reductively solidified into rigid
racial differences that are then given the imprimatur of the state through the
potential grant of patent protection.
A news report on Academia Sinica and its role in the IWPC noted that
there is a follow-up study of 600 patients in Taiwan in order to verify the
predictive accuracy of the model.191 One of the Academia Sinica
researchers asserted, “The result of the study on the island is significant in
that it will serve as the dosing guideline for people of ethnic Chinese origin.
This is the largest community in the world.”192 The report goes on to note:
The research efforts may turn out to be profitable as well. In 2005
Academia Sinica created a spin-off business called PharmiGene Inc., which
focuses on the creation of personalized medicine products. The company
has already used the scientific knowledge gained by Academia Sinica to
manufacture several gene-detection kits, including a warfarin dosing
prediction model developed in 2005.193

With PharmiGene and its race-specific patent, Academia Sinica is
positioning itself to sell its warfarin tests to “people of ethnic Chinese
origin,” not only the largest “community” in the world, but also the largest
potential market. Race, in short, persists as a viable basis for framing and
capturing a pharmacogenomic market.
Importantly, an average patent application takes at least two years to
process.194 As Academia Sinica’s race-specific patent is working its way
through the PTO (known as the “patent prosecution” process) it has
encountered some problems. To obtain patent protection for inventions, all
patent applications must meet several statutory requirements. The most
prominent of these are known as “useful[ness]” (or utility),195 “novelty,”196
190. ROGER E. SCHECHTER & JOHN R. THOMAS, INTELLECTUAL PROPERTY: THE LAW OF
COPYRIGHTS, PATENTS AND TRADEMARKS 404 (2003).
191. Meg Chang, Genetics May Hold the Key to Warfarin Dosing, TAIWAN TODAY, Mar.
13, 2009, http://taiwantoday.tw/fp.asp?xItem=49357&CtNode=427.
192. Id. (emphasis added).
193. Id.
194. U.S. Patent & Trademark Office, Frequently Asked Questions, http://www.uspto.gov/
main/faq/ (last visited Dec. 30, 2009).
195. 35 U.S.C. § 101 (2006).
196. 35 U.S.C. § 102 (2006).
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“non-obvious[ness],”197 and “specification.”198 In January 2009, the patent
examiner rejected certain claims in the application as obvious and
anticipated (i.e. not “novel”) by two patent applications filed by University of
Washington researcher Mark Rieder (also a member of the IWPC)—
particularly the second application, #20080057500 (referred to as “Rieder
II”).199 The Rieder application (a continuation of an earlier patent filed on
October 18, 2004) was titled “Methods and Compositions for Predicting
Drug Responses.”200 The application directly referenced the VKORC1 gene
and warfarin response, stating in the abstract, “the present invention
provides methods and compositions for determining individualized Warfarin
dosages based on genotype of DNA polymorphisms and haplotypes derived
from them in the VKORC1 gene.”201 Given Academia Sinica’s patent
application’s explicit focus on VKORC1, this presented something of a
problem.
In response, Yuan-Tsong Chen filed an “Inventor’s Declaration” setting
forth his reasons why the Rieder application did not negate his
submission.202 He placed race at the center of his argument as he asserted,
although only 4% [of] Caucasians carry the haplotypes [a group of linked
genes] unrelated to warfarin response, i.e., H3-H6, these haplotypes
constitute as high as 39% of the African-American population and as high
as 19% in Hispanic Americans. As another example, the total frequency of
H3-H6 is 20% in ethnic groups other than Caucasians, African-Americans,
Asians, and Hispanic-Americans. These teachings clearly indicate that
haplotypes H3-H6, which, according to Rieder II, are unrelated to warfarin
response, CANNOT be ignored in the whole human population.203

Chen is here explicitly using race to show the relevance of haplotypes H3H6 and thus differentiating his patent application from Rieder’s. He adds
race to make his claims appear novel and non-obvious. The motivation
here is not scientific, but legal and commercial. The connection between

197. 35 U.S.C. § 103 (2006).
198. 35 U.S.C. § 112 (2006).
199. See U.S. Patent & Trademark Office, Patent Application Information Retrieval Portal,
http://portal.uspto.gov/external/portal/pair (from this website: enter 11/316406 for
Application Number; select the “Image File Wrapper” tab; then select the link for “Non-Final
Rejection”) (last visited Jan. 06, 2010).
200. Methods and Compositions for Predicting Drug Responses, U.S. Patent Application
No. 20080057500 (filed Mar. 16, 2007).
201. Id.
202. YUAN-TSONG CHEN ET AL., INVENTOR DECL. UNDER 37 C.F.R. §1.132 1 (2005),
available at http://portal.uspto.gov/external/portal/pair (from this website: enter 11/316406
for Application Number; select the “Image File Wrapper” tab; then select the link for “Rule
130, 131 or 132 Affidavits”).
203. Id. at 3 (internal citations omitted).
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genes and race primarily serves the purpose of obtaining patent protection,
not of furthering science.
VII. CONCLUSION
Hearkening back to the role of patents in the case of BiDil, we can see
how the cases of Bystolic (nebivolol) and warfarin response testing are both
similar and different. The story of BiDil involved the use of race to recapitalize the value of existing generic drugs. The need to create a
patentable product in order to convince corporate backers of the drug’s
viability as a commercial product led to using race as a frame for
interpreting existing science, developing clinical trial protocols, compiling
regulatory filings, and designing marketing campaigns. Patenting and
marketing strategies mutually incentivized the use of race independent of
any specific scientific or medical utility.
The new nebivolol patent
application indicates a BiDil-like strategy to use race to extend patent life.
In contrast, the Academia Sinica patent application process has not directly
involved the reconfiguration of an existing product as racial in order to
extend patent life, but it does show how race can be used to differentiate
one product or process from another as a potential means to obtain initial
patent protection. Both models involve the exploitation of race in order to
enhance the commercial value of scientific research by creating racespecific market-niches for products. The story of warfarin testing further
demonstrates that even after specific genes for drug response are identified,
race continues to be commercially useful as a means to gain patent
protection and carve out niches in a crowded marketplace. Biotechnology
firms and biomedical professionals thus continue to embrace race as a
central component of patenting and marketing strategies, even after it has
ceased to serve any scientific purpose.

